In a study of 29 patients with melanoma treated with nivolumab or pembrolizumab, the serum IL-8 level was strongly associated with therapy response, which was validated in 19 patients with Non-small cell lung cancer (NSCLC) treated with these agents (25). The gene discussed is CXCL8; the disease is melanoma.